Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease

Attanasio, Ermanno; Russo, Pierluigi; Allen, Shannon E.

doi:10.1016/s0149-2918(01)80010-2

Cited by 9 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To address this limitation, there have been studies of maintenance (ie, the cost to maintain a level of drug therapy over some longer period of time). It is common in maintenance studies to include only drug costs, explicitly or implicitly [22,23]. Although this information may be helpful in the decision-making process, it is potentially misleading.…”

Section: Initiation Of Therapymentioning

confidence: 99%

Pharmacoeconomics of lipid-lowering drugs

Smith

2003

Curr Atheroscler Rep

View full text Add to dashboard Cite

The widespread use and high cost of lipid-lowering drugs have resulted in numerous investigations of their cost effectiveness. Pharmacoeconomic analyses have considered initiation of treatment, maintenance therapy, and long-term outcomes of lipid-lowering therapy. Analyses have yielded a number of consistent messages, but the story continues to evolve as new trials, models, and drugs are introduced. Certain medications are more efficacious and associated with more cost-effective lipid-lowering therapy initiation. Other medications are lower priced and may be more cost effective for maintenance, contingent upon having achieved lipid-lowering goals. Finally, some medications have proven long-term cost effectiveness in trials and comparative cost effectiveness in models. Research is certain to further our understanding of the costs of lipid-lowering therapy and the methods needed to optimize expenditures.

show abstract

Section: Initiation Of Therapymentioning

confidence: 99%

Pharmacoeconomics of lipid-lowering drugs

Smith

2003

Curr Atheroscler Rep

View full text Add to dashboard Cite

show abstract

“…Previous studies have used decision analytic approaches to evaluate the cost‐effectiveness of alternative statins to achieve target cholesterol reductions 15–20 . Two of these studies considered TC and LDL‐C cholesterol targets 15 and LDL‐C targets only 16 from a UK perspective.…”

Section: Introductionmentioning

confidence: 99%

The Cost‐effectiveness of a New Statin (Rosuvastatin) in the Uk NHS

Palmer

Brady

Ratcliffe

2003

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYStatins are central to the government's National Service Framework (NSF) for coronary heart disease (CHD). NHS spending on statins is currently about £500 million per annum and rising at an annual rate of 30%. Although generally considered to be a cost‐effective treatment for hyperlipidaemia and cardiovascular disease, given the high and rising expenditure on statins in the UK, there is a pressing need to ensure that the choice between available statins reflects cost‐effectiveness considerations. A decision model was developed to establish the cost‐effectiveness of treating new hypercholesterolaemic patients to UK and European target levels of blood total cholesterol (TC) and low density lipoprotein‐cholesterol (LDL‐C), using rosuvastatin, atorvastatin, simvastatin, pravastatin or fluvastatin. The model was used to estimate the proportion of patients reaching target and the associated costs over a one‐year period from the perspective of the NHS. The effectiveness of the alternative statins were modelled using data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial. Monte Carlo simulation was used to reflect uncertainty in the parameter estimates applied in the model. Rosuvastatin is demonstrated to dominate (i.e. lower costs and a higher number of patients treated to target) atorvastatin, simvastatin and pravastatin. Compared with fluvastatin, the incremental cost per additional patient to target (PTT) for rosuvastatin was £24 using LDL‐C and £83 using TC. The probability that rosuvastatin is cost‐effective exceeds 95%, provided the NHS is prepared to pay at least £35 per PTT to achieve target LDL‐C cholesterol levels (£160 for TC). The analysis demonstrates rosuvastatin is more cost‐effective than the other statins in achieving UK and European cholesterol targets.

show abstract

“…Einige der untersuchten Evaluationen beschreiben die Studienpopulation der zugrunde liegenden klinischen Studien nur unklar oder verweisen ausschließlich auf Sekundärliteraturquellen (z. B Attanasio et al 2001;,. sodass keine populationsspezifischen Merkmale identifiziert werden konnten.Die den Evaluationen zugrunde liegenden klinischen Studien untersuchen unterschiedliche Endpunkte.…”

unclassified

Einsatz von Statinen zur Sekund�rpr�vention von kardio-vaskul�ren Erkrankungen. Ein systematischer Review gesundheits�konomischer Analysen

Wild¹,

Zechmeister²

2012

View full text Add to dashboard Cite

Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease

Cited by 9 publications

References 13 publications

Pharmacoeconomics of lipid-lowering drugs

Pharmacoeconomics of lipid-lowering drugs

The Cost‐effectiveness of a New Statin (Rosuvastatin) in the Uk NHS

Einsatz von Statinen zur Sekund�rpr�vention von kardio-vaskul�ren Erkrankungen. Ein systematischer Review gesundheits�konomischer Analysen

Contact Info

Product

Resources

About